Brian Jones and Andres Tellez of Cedilla Therapeutics by Digital Biotech

Brian Jones has more than 25 years of drug discovery experience and has led the molecular discovery behind more than 20 INDs across several therapeutic areas. Most recently he spent 11 years at Novartis, where he was head of discovery chemistry for NIBR in Cambridge, Mass. Prior to that, Brian was at Merck for 16 years, initially as director of medicinal chemistry in Rahway, N.J. and subsequently as senior director at the Neuroscience Research Centre in the UK. Brian holds a Ph.D. in chemistry from Imperial College, London. He was a NATO post-doctoral fellow at Yale University.

Andres Tellez comes to Cedilla from Syros Pharmaceuticals, where he served as senior director of business development and helped secure the company’s partnerships with Incyte and Johnson and Johnson. Before joining Syros, Andres worked for several years at Cerulean Pharma, rising to director and acting head of business development. At Cerulean he served in a broad role, advancing strategic collaborations and supporting the company’s clinical development and fundraising efforts. Andres has a Ph.D. in biomedical informatics from Stanford University and an SB and M.Eng in EECS from MIT.